Table 3.
Univariate and multivariate prognostic analyses for DFS and OS in adult M0 ACC patients from TCGA.
| DFS * | Univariate | Multivariate ** | Multivariate ** | |||||||
| n | HR [95% CI] | p-Value | n | HR [95% CI] | p-Value | n | HR [95% CI] | p-Value | ||
| Age, median | 64 | 0.99 [0.97–1.02] | 0.682 | |||||||
| Sex | male vs. female | 64 | 0.79 [0.36–1.72] | 0.546 | ||||||
| ENSAT stage | 2–3 vs. 1 | 62 | 2.86 [0.67–12.2] | 0.155 | ||||||
| Pathological tumor size (pT) | pT2 vs. pT1 | 62 | 2.11 [0.48–9.30] | 1.01 × 10−2 | 56 | 2.41 [0.53–11.02] | 0.257 | 56 | 3.98 [0.82–19.29] | 0.087 |
| pT3 vs. pT1 | 6.99 [1.33–36.9] | 56 | 9.39 [1.41–62.54] | 2.07 × 10−2 | 56 | 21.1 [2.73–163.4] | 3.47 × 10−3 | |||
| pT4 vs. pT1 | 9.02 [1.58–51.6] | 56 | 20.7 [1.62–264.7] | 1.98 × 10−2 | 56 | 28.0 [2.60–301.4] | 5.98 × 10−3 | |||
| Pathological lymph node (pN) | pN1 vs. pN0 | 62 | 1.81 [0.42–7.78] | 0.423 | ||||||
| Surgical margins status | R1-R2 vs. R0 | 56 | 5.10 [1.13–23.0] | 3.38 × 10−2 | 56 | 1.04 [0.13–8.59] | 0.970 | 56 | 0.55 [0.08–3.69] | 0.540 |
| Weiss classification | high vs. low | 49 | 3.00 [0.94–9.52] | 0.063 | ||||||
| Steroid hormone secretion excess | yes vs. no | 59 | 2.50 [0.93–6.71] | 0.068 | ||||||
| Adjuvant mitotane | yes vs. no | 61 | 1.44 [0.65–3.19] | 0.372 | ||||||
| Adjuvant radiotherapy | yes vs. no | 62 | 1.67 [0.66–4.21] | 0.282 | ||||||
| MKI67 mRNA status | high vs. low | 64 | 3.60 [1.64–7.89] | 1.38 × 10−3 | 56 | 1.65 [0.58–4.69] | 0.350 | 56 | 1.19 [0.38–3.73] | 0.760 |
| TP53 mutation status | wt vs. mt | 64 | 0.28 [0.09–0.86] | 2.58 × 10−2 | 56 | 0.84 [0.11–6.41] | 0.870 | 56 | 0.72 [0.13–4.07] | 0.707 |
| FATE1 class | high vs. low | 64 | 2.51 [1.09–5.74] | 2.98 × 10−2 | 56 | 5.18 [1.53–17.5] | 8.16 × 10−3 | |||
| FATE1, continuous value | 64 | 1.14 [1.04–1.25] | 3.79 × 10−3 | 56 | 1.23 [1.08–1.40] | 1.84 × 10−3 | ||||
| OS * | Univariate | Multivariate ** | Multivariate ** | |||||||
| n | HR [95% CI] | p-Value | n | HR [95% CI] | p-Value | n | HR [95% CI] | p-Value | ||
| Age, median | 64 | 1.00 [0.96–1.03] | 0.834 | |||||||
| Sex | male vs. female | 64 | 1.45 [0.51–4.15] | 0.485 | ||||||
| ENSAT stage | 2–3 vs. 1 | 62 | 2.97 [0.38–23.0] | 0.298 | ||||||
| Pathological tumor size (pT) | pT2 vs. pT1 | 62 | 1.85 [0.22–15.5] | 5.56 × 10−3 | 56 | 5.7 [0.48–67.17] | 0.167 | 56 | 9.0 [0.68–118.0] | 0.096 |
| pT3 vs. pT1 | 6.83 [0.57–81.8] | 56 | 29.0 [1.20–700.7] | 3.83 × 10−2 | 56 | 37.33 [1.46–952] | 2.85 × 10−2 | |||
| pT4 vs. pT1 | 21.6 [2.08–224] | 56 | 16.3 [0.68–393.8] | 0.085 | 56 | 21.07 [1.00–443] | 4.99 × 10−2 | |||
| Pathological lymph node (pN) | pN1 vs. pN0 | 62 | 0.00 [0.00 - Inf.] | 0.998 | ||||||
| Surgical margins status | R1-R2 vs. R0 | 56 | 35.7 [3.22–395] | 3.59 × 10−3 | 56 | 3.47 [0.20–60.72] | 0.395 | 56 | 2.84 [0.17–48.4] | 0.472 |
| Weiss classification | high vs. low | 49 | 4.79 [0.92–24.8] | 0.062 | ||||||
| Steroid hormone secretion excess | yes vs. no | 59 | 3.17 [0.70–14.3] | 0.134 | ||||||
| Adjuvant mitotane | yes vs. no | 61 | 2.18 [0.65–7.29] | 0.208 | ||||||
| Adjuvant radiotherapy | yes vs. no | 62 | 1.06 [0.23–4.84] | 0.938 | ||||||
| MKI67 mRNA status | high vs. low | 64 | 8.87 [2.45–32.2] | 8.99 × 10−4 | 56 | 5.28 [0.97–28.80] | 0.055 | 56 | 3.26 [0.51–20.9] | 0.212 |
| TP53 mutation status | wt vs. mt | 64 | 0.15 [0.04–0.60] | 7.79 × 10−3 | 56 | 0.21 [0.02–2.08] | 0.183 | 56 | 0.18 [0.02–1.49] | 0.112 |
| FATE1 class | high vs. low | 64 | 3.66 [1.01–13.2] | 4.78 × 10−2 | 56 | 8.74 [0.95–80.52] | 5.60 × 10−2 | |||
| FATE1, continuous value | 64 | 1.19 [1.06–1.34] | 4.06 × 10−3 | 56 | 1.23 [1.01–1.49] | 4.34 × 10−2 | ||||
* n = 64 M0 patients; ** the multivariate analysis was performed with FATE1 both as a binary variable (left) and as a continuous variable (right).